Tuesday September 25, 2018 06:56

General Press Release : 05 Nov 2007

Asia’s 1st International Exhibition & Conference on Building Maintenance and Asset Management General—05 Nov 07

Building Maintenance & Asset Management Expo Asia 2008 With increasing business and financial pressures, industries across Asia now see the importance of maintaining its plants, machinery and building assets. As companies focus on core business a

Photo Release: Halloween funky dance frontrunners ".S.N.T Dance" and "Le Deste’" to be awarded in General—05 Nov 07

Mrs. Ratana Anuntanupong (center), Vice President - Marketing of Rangsit Plaza Ltd., the operator of Future Park Rangsit Shopping Complex, bestowed scholarship and prizes to winner teams “.S.N.T Dance” of the youth category and “Le D

AsiaNet Daily Summary, Press Releases for Monday, November 5, 2007 General—05 Nov 07

HEART ATTACK... TOKYO and INDIANAPOLIS: In the pivotal Phase III head-to-head TRITON TIMI-38 clinical trial, the investigational antiplatelet agent prasugrel produced a highly significant 19 per cent reduction in relative risk for the composite endpoint

New Non-Clinical Data Links DYNEPO(R) (Epoetin Delta) to Reduced Angiogenic General—05 Nov 07

New data presented today at the 40th annual American Society of Nephrology (ASN) meeting and scientific exposition in San Francisco, CA, USA, show that epoetin delta -- the only erythropoiesis-stimulating agent (ESA) produced in a human cell line -- has l

Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against General—05 Nov 07

Duke Clinical Research Institute to lead multinational study with investigational compound; will include 10,000 medically managed patients with acute coronary syndrome A large Phase III clinical trial is anticipated to begin in the second quarter of 20

In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in General—05 Nov 07

Investigational compound reduces risk of major cardiovascular events by 19 percent, significantly improves net clinical benefit despite increased bleeding In the pivotal Phase III head-to-head TRITON TIMI-38 clinical trial, the investigational antiplat